Does Singulair Cause Drowsiness? Side Effects and Safety Guide (2026)

Singulair (montelukast) can cause drowsiness or somnolence in some individuals, although it is not classified as a sedative medication. While clinical trials reported drowsiness in a small percentage of users, real-world patient reports often highlight fatigue and lethargy as notable side effects. Understanding how this medication interacts with your central nervous system is essential for safety.

Singulair, known generically as montelukast sodium, has been a cornerstone in the treatment of chronic asthma, exercise-induced bronchoconstriction, and seasonal allergic rhinitis for decades. As we move through 2026, healthcare providers continue to refine their understanding of how this leukotriene receptor antagonist affects various patients differently. While its primary goal is to reduce inflammation in the airways, its systemic reach means that secondary effects, such as changes in alertness or sleep patterns, are common topics of clinical discussion.

Understanding Singulair (Montelukast) and Its Mechanism

To understand why a medication like Singulair might lead to drowsiness, one must first understand what it does within the body. Singulair is a selective leukotriene receptor antagonist. Leukotrienes are chemicals your body releases when you breathe in an allergen, such as pollen. These chemicals cause swelling in your lungs and tightening of the muscles around your airways, which results in asthma symptoms and allergic reactions.

Unlike antihistamines, which block histamine receptors, montelukast specifically targets the cysteinyl leukotriene (CysLT1) receptor. By binding to these receptors, the drug prevents leukotrienes from triggering inflammation and mucus production. Because these receptors are primarily located in the airways, the drug is highly effective for respiratory issues. However, research has shown that leukotriene receptors also exist in other parts of the body, including the brain. This presence in the central nervous system is why some patients experience neurological or "neuropsychiatric" side effects, ranging from vivid dreams to the drowsiness in question.

In the 2026 clinical landscape, the use of montelukast remains widespread, but it is often accompanied by more rigorous screening for pre-existing neurological conditions. Because the drug can cross the blood-brain barrier—albeit to a limited extent—it has the potential to influence neurotransmission or induce a state of lethargy in sensitive individuals. This is not a "sleep-inducing" effect in the way a hypnotic or a first-generation antihistamine works, but rather a systemic side effect of altering chemical signaling.

Is Drowsiness a Common Side Effect of Singulair?

When examining the frequency of drowsiness, it is important to distinguish between "common" and "clinically significant." In the original clinical trials for Singulair, somnolence (drowsiness) was reported in approximately 1% to 2% of patients. This is relatively low compared to other medications like Benadryl (diphenhydramine), where drowsiness is expected in a majority of users.

However, "real-world" data collected through 2026 suggests that the incidence may be higher in specific populations or when combined with other factors. Fatigue and a general sense of "brain fog" are frequently reported by patients who may not necessarily fall asleep during the day but feel a reduction in their overall energy levels. This distinction is vital for those who operate heavy machinery or have high-demand cognitive jobs.

The onset of drowsiness usually occurs within the first few days of starting the medication or following an increase in dosage. For some, the body adjusts to the presence of montelukast, and the sleepiness tapers off after two to three weeks. For others, the lethargy remains a persistent hurdle that requires a change in medication timing or a switch to an alternative therapy.

Why Some People Experience Fatigue on Montelukast

The experience of fatigue while taking Singulair can be attributed to several physiological and psychological factors. First, the drug's impact on the central nervous system (CNS) cannot be ignored. While it is designed for the lungs, any drug that modulates inflammatory mediators can have secondary effects on the "sickness behavior" pathways in the brain. These pathways are responsible for making us feel tired when our immune system is active.

Secondly, Singulair is known to affect sleep architecture. Many patients report vivid dreams, nightmares, or even sleepwalking. If a patient is experiencing disrupted REM sleep or frequent awakenings due to intense dreaming, they will naturally feel drowsy and unrefreshed the following day. In this case, the drowsiness is an indirect result of poor sleep quality rather than a direct sedative effect of the pill itself.

Lastly, there is the factor of metabolic variation. Genetic differences in the way the liver processes montelukast via the cytochrome P450 enzyme system can lead to higher systemic levels of the drug in some individuals. Higher concentrations in the blood can increase the likelihood and intensity of side effects, including lethargy and dizziness.

Comparing Singulair Drowsiness to Antihistamines

Patients often confuse Singulair with antihistamines like Zyrtec (cetirizine) or Claritin (loratadine) because they are both used to treat allergies. However, their side effect profiles regarding drowsiness are distinct.

As shown in the table, while Singulair is less likely than a traditional antihistamine to cause daytime sleepiness, it carries unique risks related to mental health and sleep quality that are not typically seen with antihistamines. This makes it a complex choice for patients who are already prone to fatigue or mood disorders.

The FDA Boxed Warning and Neuropsychiatric Concerns

It is impossible to discuss Singulair in 2026 without addressing the FDA Boxed Warning. Initially issued in 2020, this warning remains the most serious caution the FDA provides. The warning highlights the risk of serious neuropsychiatric events, including agitation, aggression, depression, sleep disturbances, and suicidal thoughts or actions.

Drowsiness and fatigue can sometimes be early indicators of these more serious mood changes. For instance, a patient might feel "lethargic" as a symptom of developing depression linked to the medication. Because of this, the FDA recommends that Singulair only be used for allergic rhinitis when other treatments have failed or are not tolerated. For asthma, the benefits must be weighed carefully against the potential for mental health changes.

If you or a family member notices a significant shift in energy levels accompanied by mood swings or dark thoughts, it is imperative to contact a healthcare provider immediately. The drowsiness may be more than just a physical reaction; it could be part of a broader psychological response to the drug.

Managing Drowsiness: Timing and Dosage

The standard recommendation for taking Singulair—specifically for asthma—is to take it once daily in the evening. This timing is strategic for two reasons:

1. Asthma Symptoms: Asthma symptoms often worsen during the night or early morning hours. Taking the dose in the evening ensures peak plasma levels of the drug are present when the body needs them most.
2. Side Effect Mitigation: If the drug does cause mild drowsiness or dizziness, taking it before bed allows the patient to sleep through the peak side-effect window.

For those using Singulair strictly for seasonal allergies, the timing is more flexible, but evening dosing remains a popular strategy for those who experience daytime fatigue. It is important not to double a dose if one is missed, as higher concentrations of montelukast are significantly more likely to trigger CNS-related side effects.

If daytime sleepiness persists despite evening dosing, a physician may suggest a lower dose (if appropriate for the patient's age and weight) or may investigate whether the drowsiness is caused by a different underlying condition, such as sleep apnea or a secondary allergy medication.

Practical Recommendations for Patients

If you are prescribed Singulair and are concerned about drowsiness, consider the following steps to ensure safety and efficacy:

• Monitor the First Two Weeks: Keep a "symptom diary" during the first 14 days of treatment. Note your energy levels at various points of the day and record the quality of your sleep.
• Evaluate Concomitant Medications: Ensure your doctor knows about every other supplement or medication you take. Combining Singulair with other medications that cause CNS depression, such as benzodiazepines or certain cough medicines, can compound the drowsiness.
• Assess Driving Safety: Before driving long distances or performing dangerous tasks, observe how a single dose affects you. Even if you don't feel "sleepy," your reaction times could be subtly slowed.
• Discuss Alternatives: If fatigue is interfering with your quality of life, discuss leukotriene modifiers like zafirlukast or inhaled corticosteroids with your doctor. In 2026, there are more options than ever for personalized asthma and allergy management.
• Stay Hydrated: Dehydration can mimic the "brain fog" associated with Singulair. Maintaining proper fluid intake can help the liver and kidneys process the medication efficiently.

Frequently Asked Questions

Does Singulair drowsiness go away over time?

In many cases, yes. The body often undergoes a period of "acclimatization" where the initial lethargy or dizziness subsides within the first two to three weeks of consistent use. However, if the fatigue is caused by disrupted sleep patterns (vivid dreams), it may persist until the medication is discontinued or the timing is adjusted.

Can I take Singulair in the morning to avoid vivid dreams at night?

While some patients find relief from nightmares by taking the medication in the morning, this can increase the risk of daytime drowsiness. You should consult your physician before changing your dosing schedule, especially if you are taking Singulair for asthma, as morning dosing may be less effective at preventing nighttime asthma attacks.

Is drowsiness more common in children taking Singulair?

Clinical data suggests that children may experience side effects differently. While irritability and hyperactivity are frequently noted in pediatric patients, some children do experience significant somnolence. Parents should monitor their children's school performance and energy levels closely after starting the 4mg or 5mg chewable tablets.

Can I drink alcohol while taking Singulair?

It is generally advised to limit alcohol consumption while taking montelukast. Both substances can affect the central nervous system and the liver. Combining them may increase the risk of dizziness, drowsiness, and impaired judgment.

How does Singulair compare to Zyrtec for sleepiness?

Generally, Singulair is less likely to cause direct sedation than Zyrtec (cetirizine). In clinical studies, about 10% of Zyrtec users reported drowsiness, compared to roughly 1-2% of Singulair users. However, Singulair's side effects are more likely to involve complex mood and sleep disturbances.

Conclusion and Next Actions

While Singulair is not primarily a sedative, the link between montelukast and drowsiness is well-documented and should not be ignored. Whether it is a direct result of the drug crossing the blood-brain barrier or an indirect consequence of vivid, interrupted sleep, fatigue can significantly impact your daily life.

If you are currently experiencing drowsiness on Singulair, your next action should be to consult your prescribing physician. Do not stop taking the medication abruptly, especially if it is for asthma control, as this could lead to a sudden worsening of respiratory symptoms. Instead, discuss whether an evening dosing schedule is right for you, or if a different class of medication might provide the relief you need without the accompanying lethargy.